ASH 2021 | Analyzing the cost-effectiveness of CPX-351 in patients with AML
In this video, Jan Philipp Bewersdorf, MD, Yale University, New Haven, CT, summarizes the findings from a recent Phase III trial comparing the use of liposomal cytarabine – daunorubicin (CPX-351) vs conventional cytarabine – daunorubicin chemotherapy in patients with acute myeloid leukemia (AML) (NCT01696084). Using data from this trial, Dr Bewersdorf then reports on the results from a partitioned survival analysis that evaluated the cost-effectiveness of CPX-351. In the analysis, Dr Bewersdorf explains how the cost-effectiveness ratio was calculated and uses this to determine whether CPX-351 is currently cost-effective as a treatment option for patients with AML. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
